Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb dose-ranging study of GIA632 in non-segmental vitiligo
jRCT2031260030Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of GIA632 in Vitiligo (5 arms), sponsored by Novartis. Primary endpoint: Facial Vitiligo Area Scoring Index (F-VASI). Started Jun 2026; status: recruiting.
02
Drugs
GIA632
03
Conditions
Vitiligo
Beyond the preview
Go deeper on jRCT2031260030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260030.